Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: A case-control study

Lancet

Volumn 353, Issue 9150, 1999, Pages 351-354

  Moshfegh, Khatereh ^a   Wuillemin, Walter A ^a   Redondo, Maurice ^a   Lämmle, Bernhard ^a   Beer, Jürg H ^a   Liechti Gallati, Sabina ^a   Meyer, Beat J ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; COLLAGEN; FIBRINOGEN; GLYCOPROTEIN IB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLATELET GLYCOPROTEIN IA/IIA RECEPTOR; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DNA SEQUENCE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR DENSITY; REGRESSION ANALYSIS; RISK; RISK FACTOR; SINGLE STRAND CONFORMATION POLYMORPHISM; SMOKING; THROMBOCYTE FUNCTION; THROMBOGENESIS;

EID: 0001218842     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)06448-4     Document Type: Article

References (30)

1. De Wood M.A., Spores J., Notske R., et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 303:1980;897-902.
2. Davies M.J. Acute coronary thrombosis - the role of plaque disruption and its initiation and prevention. Eur Heart J. 16:1995;3-7.
3. Fitzgerald D.J., Roy L., Catella F., FitzGerald G.A. Platelet activation in unstable coronary disease. N Engl J Med. 315:1986;983-989.
4. Fuster V, Badimon L, Badimon JJ, Chesebro JH, The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 252-50 and 310-18.
5. Altman R., Carreras L., Diaz R., et al. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:1994;81-106.
6. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
7. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized efficacy study of tirofiban for outcomes and restenosis. Circulation 1997; 96: 1445-53.
8. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
9. PRISM-PLUS Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 338:1998;1488-1497.
10. Weiss E.J., Bray P.F., Tayback M., et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 334:1996;1090-1094.
11. Walter D.H., Schachinger V., Elsner M., Dimmeler S., Zeiher A.M. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 350:1997;1217-1219.
12. Ridker P.M., Hennekens C.H., Schmitz C., Stampfer M.J., Lindpaintner K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet. 349:1997;385-388.
13. Newman P.J. Platelet alloantigens: cardiovascular as well as immunological risk factors? Lancet. 349:1997;370-371.
14. Nurden A.T. Platelet glycoprotein IIIa polymorphism and coronary thrombosis thrombosis. Lancet. 350:1997;1189-1191.
15. Nurden A.T. Polymorphisms of human platelet membrane glycoproteins: structure and clinical significance. Thromb Haemost. 74:1995;345-351.
16. Kunicki T.J., Orchekowski R., Annis D., Honda Y. Variability of integrin alpha 2 beta 1 activity on human platelets. Blood. 82:1993;2693-2703.
17. Kunicki T.J., Kritzik M., Annis D.S., Nugent D.J. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood. 89:1997;1939-1943.
18. Carroll V.A., Griffiths M.R., Geiger M., et al. Plasma protein C inhibitor is elevated in survivors of myocardial infarction. Arterioscler Thromb Vasc Biol. 17:1997;114-118.
19. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 17:1957;237-246.
20. Beelman C.A., Parker R. Degradation of mRNA in eukaryotes. Cell. 81:1995;179-183.
21. Beutler E., Kuhl W. Linkage between a PvuII restriction fragment length polymorphism and G6PD A-202A/376G: evidence for a single origin of the common G6PD A-mutation. Hum Genet. 85:1990;9-11.
22. Beutler E., West C., Gelbart T. Polymorphisms in the human glucocerebrosidase gene. Genomics. 12:1992;795-800.
23. Hertel K.J., Lynch K.W., Maniatis T. Common themes in the function of transcription and splicing enhancers. Curr Opin Cell Biol. 9:1997;350-357.
24. Richard I., Beckmann J.S. How neutral are synonymous codon mutations? Nat Genet. 10:1995;259.
25. Burke A.P., Farb A., Malcom G.T., Liang Y.H., Smialek J., Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 336:1997;1276-1282.
26. Sharp D.S., Benowitz N.L., Bath P.M., Martin J.F., Beswick A.D., Elwood P.C. Cigarette smoking sensitizes and desensitizes impedance-measured ADP-induced platelet aggregation in whole blood. Thromb Haemost. 74:1995;730-735.
27. Cryer P.E., Haymond M.W., Santiago J.V., Shah S.D. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med. 295:1976;573-577.
28. Siess W., Lorenz R., Roth P., Weber P.C. Plasma catecholamines, platelet aggregation and associated thromboxane formation after physical exercise, smoking or norepinephrine infusion. Circulation. 66:1982;44-48.
29. Huang E.M., Detwiler T.C. Characteristics of the synergistic actions of platelet agonists. Blood. 57:1981;685-691.
30. Kirchhofer D., Tschopp T.B., Steiner B., Baumgartner H.R. Role of collagen-adherent platelets in mediating fibrin formation in flowing whole blood. Blood. 86:1995;3815-3822.